These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1500 related articles for article (PubMed ID: 30736840)

  • 1. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the wnt/β-catenin pathway.
    Liu G; Liu S; Cao G; Luo W; Li P; Wang S; Chen Y
    Exp Cell Res; 2019 Jun; 379(1):83-91. PubMed ID: 30904482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer.
    Ma S; Wei H; Wang C; Han J; Chen X; Li Y
    Cell Mol Biol Lett; 2021 Dec; 26(1):52. PubMed ID: 34895159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.
    Yuan LJ; Li JD; Zhang L; Wang JH; Wan T; Zhou Y; Tu H; Yun JP; Luo RZ; Jia WH; Zheng M
    Cell Death Dis; 2014 May; 5(5):e1247. PubMed ID: 24853425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
    Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
    Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer.
    Yuan XN; Shao YC; Guan XQ; Liu Q; Chu MF; Yang ZL; Li H; Zhao S; Tian YH; Zhang JW; Wei L
    Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119716. PubMed ID: 38547933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
    Chen H; Pan H; Qian Y; Zhou W; Liu X
    Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.